Cargando…

A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany

BACKGROUND: With atrial fibrillation (AF) the risk of stroke is 4.2-fold increased to a comparable population without AF. This risk decreases by up to 70% if AF is detected early enough and effective stroke preventive measures are taken as recommended by international guidelines. Long-term studies f...

Descripción completa

Detalles Bibliográficos
Autores principales: Birkemeyer, Ralf, Müller, Alfred, Wahler, Steffen, von der Schulenburg, Johann-Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282133/
https://www.ncbi.nlm.nih.gov/pubmed/32519034
http://dx.doi.org/10.1186/s13561-020-00274-z
_version_ 1783544072395292672
author Birkemeyer, Ralf
Müller, Alfred
Wahler, Steffen
von der Schulenburg, Johann-Matthias
author_facet Birkemeyer, Ralf
Müller, Alfred
Wahler, Steffen
von der Schulenburg, Johann-Matthias
author_sort Birkemeyer, Ralf
collection PubMed
description BACKGROUND: With atrial fibrillation (AF) the risk of stroke is 4.2-fold increased to a comparable population without AF. This risk decreases by up to 70% if AF is detected early enough and effective stroke preventive measures are taken as recommended by international guidelines. Long-term studies found large number of subjects with undiagnosed AF. Preventicus Heartbeats” is a hands-on screening tool for use on smartphone to diagnose AF with high sensitivity and specificity. The aim of this study is to research the cost-effectiveness of systematic screening for AF with this smartphone application. METHOD: Employing a Markov model we analysed the cost-effectiveness of the “Preventicus Heartbeats” screening for Germany, i.e. from the perspective of German statutory sick funds. RESULTS: For a cohort of 10,000 insured 75-year-old the use of the diagnostic app could avoid 60 strokes in the remaining lifetime thereof 32 strokes in the next four years. Former models have applied similar cohorts. The same cohort showed an increase in quality-adjusted life years (QALY) in the remaining lifetime of 165 QALYs in the scenario with screening versus. without screening and a decrease in discounted lifetime costs (including risk compensation effects) of €129 per participant (€148 for male, €114 for female participants). CONCLUSIONS: The modelling demonstrates the health benefits and economic effects of an implementation of a systematic screening on AF with “Preventicus Heartbeats”, given the perspective of the German payer, the statutory health care system.
format Online
Article
Text
id pubmed-7282133
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-72821332020-06-10 A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany Birkemeyer, Ralf Müller, Alfred Wahler, Steffen von der Schulenburg, Johann-Matthias Health Econ Rev Research BACKGROUND: With atrial fibrillation (AF) the risk of stroke is 4.2-fold increased to a comparable population without AF. This risk decreases by up to 70% if AF is detected early enough and effective stroke preventive measures are taken as recommended by international guidelines. Long-term studies found large number of subjects with undiagnosed AF. Preventicus Heartbeats” is a hands-on screening tool for use on smartphone to diagnose AF with high sensitivity and specificity. The aim of this study is to research the cost-effectiveness of systematic screening for AF with this smartphone application. METHOD: Employing a Markov model we analysed the cost-effectiveness of the “Preventicus Heartbeats” screening for Germany, i.e. from the perspective of German statutory sick funds. RESULTS: For a cohort of 10,000 insured 75-year-old the use of the diagnostic app could avoid 60 strokes in the remaining lifetime thereof 32 strokes in the next four years. Former models have applied similar cohorts. The same cohort showed an increase in quality-adjusted life years (QALY) in the remaining lifetime of 165 QALYs in the scenario with screening versus. without screening and a decrease in discounted lifetime costs (including risk compensation effects) of €129 per participant (€148 for male, €114 for female participants). CONCLUSIONS: The modelling demonstrates the health benefits and economic effects of an implementation of a systematic screening on AF with “Preventicus Heartbeats”, given the perspective of the German payer, the statutory health care system. Springer Berlin Heidelberg 2020-06-09 /pmc/articles/PMC7282133/ /pubmed/32519034 http://dx.doi.org/10.1186/s13561-020-00274-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Birkemeyer, Ralf
Müller, Alfred
Wahler, Steffen
von der Schulenburg, Johann-Matthias
A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany
title A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany
title_full A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany
title_fullStr A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany
title_full_unstemmed A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany
title_short A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany
title_sort cost-effectiveness analysis model of preventicus atrial fibrillation screening from the point of view of statutory health insurance in germany
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282133/
https://www.ncbi.nlm.nih.gov/pubmed/32519034
http://dx.doi.org/10.1186/s13561-020-00274-z
work_keys_str_mv AT birkemeyerralf acosteffectivenessanalysismodelofpreventicusatrialfibrillationscreeningfromthepointofviewofstatutoryhealthinsuranceingermany
AT mulleralfred acosteffectivenessanalysismodelofpreventicusatrialfibrillationscreeningfromthepointofviewofstatutoryhealthinsuranceingermany
AT wahlersteffen acosteffectivenessanalysismodelofpreventicusatrialfibrillationscreeningfromthepointofviewofstatutoryhealthinsuranceingermany
AT vonderschulenburgjohannmatthias acosteffectivenessanalysismodelofpreventicusatrialfibrillationscreeningfromthepointofviewofstatutoryhealthinsuranceingermany
AT birkemeyerralf costeffectivenessanalysismodelofpreventicusatrialfibrillationscreeningfromthepointofviewofstatutoryhealthinsuranceingermany
AT mulleralfred costeffectivenessanalysismodelofpreventicusatrialfibrillationscreeningfromthepointofviewofstatutoryhealthinsuranceingermany
AT wahlersteffen costeffectivenessanalysismodelofpreventicusatrialfibrillationscreeningfromthepointofviewofstatutoryhealthinsuranceingermany
AT vonderschulenburgjohannmatthias costeffectivenessanalysismodelofpreventicusatrialfibrillationscreeningfromthepointofviewofstatutoryhealthinsuranceingermany